We read with interest the letter sent by JJ Egea-Guerrero et al. The authors agree to the comment of the review1 that the routine use of biomarkers cannot be recommended in the differential diagnosis of inflammation from sepsis. The same conclusion has been achieved by Seoane et al. in a recent article.2

Egea-Guerrero et al. refer to one preliminary report about the diagnostic value of C-Reactive Protein and Procalcitonin3 in this population. The authors processed and analyzed 157 samples of 17 severe burn patients. The authors suggested that changes in Procalcitonin over time differentiated patients with sepsis and patients without sepsis only based in the ROC curves, but they did not provide data of sensitivity, specificity and likelihood ratios of different cut-off values that could help clinicians in differential diagnosis. We agree with them that it is necessary new well-designed studies to provide new insights on this topic.